Creativ-Ceutical is now part of our team. Learn more here.
Log in or register to see all Alerts
Log in Register
Market Access Alerts >December 2021>Scotland
New HTA Decisions in Scotland
December 2021
Drug name
ORFADIN® (nitisinone)
Company
Swedish Orphan Biovitrum
Decision date
05/11/2021
About PHMR
Therapeutic area
Genetic conditions
Therapeutic sub area
Genetic conditions: general and other
Decision
Not recommended
Indication
Treatment of adult patients with alkaptonuria (AKU).
Decision Detail
In the absence of a submission from the holder of the marketing authorisation, nitisinone (Orfadin®) is not recommended for use within NHS Scotland.
Summary
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result it cannot be recommended for use within NHS Scotland.


PHMR
Berkeley Works
Berkley Grove
London
NW1 8XY

+44 (0)20 3432 7450

info@phmr.com


 Understanding Payers

 Generating Evidence

 Developing Strategies

 Communicating Value

 Market Access Alerts

 Careers

 About us

 Contact us

 Cookie policy

 Privacy